Gaël Dournes

Prof. Dr. Gaël Dournes


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2016 in European Radiology
Verified
Journal Article
Closed access
PDF file
GDGaël Dournes
Gaël Dournes
FMFanny Menut
Fanny Menut
JMJulie Macey
Julie Macey
MFMichaël Fayon
Michaël Fayon
JCJean-François Chateil
Jean-François Chateil
FLFrançois Laurent
François Laurent

11 September 2018 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
PDF file
GDGaël Dournes
Gaël Dournes
JYJoseph Yazbek
Joseph Yazbek
WBWadie Benhassen
Wadie Benhassen
IBilyes Benlala
ilyes Benlala
EBElodie Blanchard
Elodie Blanchard
FLFrançois Laurent
François Laurent

17 December 2020 in Chest
Verified
Journal Article
Open access
GDGaël Dournes
Gaël Dournes
LWLaura L. Walkup
Laura L. Walkup
IBIlyes Benlala
Ilyes Benlala
MWMatthew M. Willmering
Matthew M. Willmering
JMJulie Macey
Julie Macey
JWJason C. Woods
Jason C. Woods
To assess airway and lung parenchymal damage noninvasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging because of technical difficulties such as low proton density and respiratory and cardiac motion. However, technological breakthroughs have emerged that dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, and contrast). At the same time, novel treatments have changed the landscape of CF clinical care. In this contemporary context, there is now consensus that lung MRI can be used clinically to assess CF in a radiation-free manner and to enable quantification of lung disease severity. MRI can now achieve three-dimensional, high-resolution morphologic imaging, and beyond this morphologic information, MRI may offer the ability to sensitively differentiate active inflammation vs scarring tissue. MRI could also characterize various forms of inflammation for early guidance of treatment. Moreover, functional information from MRI can be used to assess regional, small-airway disease with sensitivity to detect small changes even in patients with mild CF. Finally, automated quantification methods have emerged to support conventional visual analyses for more objective and reproducible assessment of disease severity. This article aims to review the most recent developments of lung MRI, with a focus on practical application and clinical value in CF, and the perspectives on how these modern techniques may converge and impact patient care soon.

1 October 2017 in Radiology
Verified
Journal Article
Closed access
GDGaël Dournes
Gaël Dournes
PBPatrick Berger
Patrick Berger
JRJohn Refait
John Refait
JMJulie Macey
Julie Macey
SBStephanie Bui
Stephanie Bui
FLFrançois Laurent
François Laurent
Because allergic bronchopulmonary aspergillosis diagnosis requires a combination of criteria, including imaging criteria, this study suggests that the inverted mucoid impaction signal sign is a valuable alternative to the hyperattenuating mucus sign in the care of patients with cystic fibrosis, without concern about radiation dose accumulation during lifelong treatment. PurposeTo assess the diagnostic accuracy of mucus contrast characterization by using magnetic resonance (MR) imaging to discriminate allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF).Materials and MethodsThe study was approved by the local Ethics Committee, and all patients or their parents gave written informed consent. One hundred ten consecutive patients with CF were screened between January 2014 and July 2015. All patients underwent a non—contrast material–enhanced MR protocol that included routine T1-weighted and T2-weighted sequences. The presence of mucus with both high T1 and low T2 signal intensities and the so-called inverted mucoid impaction signal (IMIS) sign was qualitatively and quantitatively assessed by two physicians who were blinded to all other data. The reference standard for a diagnosis of ABPA was the criteria of the Cystic Fibrosis Foundation Consensus Conference. ABPA status was followed up for 1 year. Reproducibility was assessed by using the κ test, correlati...

15 July 2021 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
GDGaël Dournes
Gaël Dournes
CHChase S. Hall
Chase S. Hall
MWMatthew M. Willmering
Matthew M. Willmering
ABAlan S. Brody
Alan S. Brody
JMJulie Macey
Julie Macey
JWJason C. Woods
Jason C. Woods
Background: Chest computed tomography (CT) remains the imaging standard for demonstrating cystic fibrosis (CF) airway structural diseasein vivo. However, visual scoring systems as an outcome measure are time consuming, require training and lack high reproducibility. Our objective was to validate a fully automated artificial intelligence (AI)-driven scoring system of CF lung disease severity.Methods: Data were retrospectively collected in three CF reference centres, between 2008 and 2020, in 184 patients aged 4–54 years. An algorithm using three 2D convolutional neural networks was trained with 78 patients’ CT scans (23 530 CT slices) for the semantic labelling of bronchiectasis, peribronchial thickening, bronchial mucus, bronchiolar mucus and collapse/consolidation. 36 patients’ CT scans (11 435 CT slices) were used for testingversusground-truth labels. The method's clinical validity was assessed in an independent group of 70 patients with or without lumacaftor/ivacaftor treatment (n=10 and n=60, respectively) with repeat examinations. Similarity and reproducibility were assessed using the Dice coefficient, correlations using the Spearman test, and paired comparisons using the Wilcoxon rank test.Results: The overall pixelwise similarity of AI-drivenversusground-truth labels was good (Dice 0.71). All AI-driven volumetric quantifications had moderate to very good correlations to a visual imaging scoring (p<0.001) and fair to good correlations to forced expiratory volume in 1 s % predicted at pulmonary function tests (p0.99).Conclusion: AI allows fully automated volumetric quantification of CF-related modifications over an entire lung. The novel scoring system could provide a robust disease outcome in the era of effective CF transmembrane conductance regulator modulator therapy.

1 July 2023 in Radiology
Verified
Journal Article
Closed access
ALArthur Longuefosse
Arthur Longuefosse
JRJulien Raoult
Julien Raoult
IBilyes Benlala
ilyes Benlala
BSBaudouin Denis de Senneville
Baudouin Denis de Senneville
TBThomas Benkert
Thomas Benkert
GDGaël Dournes
Gaël Dournes